78th Annual Meeting of the Northeastern Section of the AUA (2026)
Availability
No future session
Cost
$0.00
Credit Offered
17.75 AMA PRA Category 1 Credit Credits
17.75 Participation Credits
Urologic abnormalities and diseases present with diverse clinical signs and symptoms and require accurate diagnosis and management aligned with a rapidly changing standard of care. Continuing education is needed on the current presentation and work-up of urologic conditions, the appropriate and cost-effective use of new technologies, and the latest pharmacologic, device-based, and operative management options. Advances in medical science and urologic practice demand ongoing learning grounded in basic and clinical research; presentation and discussion of peer-reviewed, abstract-reviewer–selected summaries provide cutting-edge updates for clinicians and essential feedback for researchers translating investigation into practice. The educational needs for the 78th Annual Meeting are organized into four clinical topic areas. In clinical-trials research in urologic oncology, there is a need for greater knowledge of recent and ongoing trials and for competence in applying their findings to individualized, value-conscious selection among surgical, systemic, and organ-sparing options. In clinical-trials research in benign urology, there is a need for greater knowledge of emerging trial data in benign lower-urinary-tract disease and for competence in risk-stratified, minimally invasive, and practice-based approaches. In surgical practice, there is a need for greater knowledge of recent surgical device advancements and operative and office-based techniques and for competence in their appropriate, patient-specific use. In clinical practice, there is a need for greater knowledge of recently updated guidelines and contemporary evidence across clinical and sexual-medicine topics and for competence in identification, counseling, individualized treatment, and appropriate referral. A cross-cutting need is the strengthening of collaborative and practice-based clinical-trial infrastructure across U.S. and Canadian settings. Advanced Practice Providers (APPs) are critical in the complex management of urologic patients. The aging of the US population and anticipated shortage of urologists contributes to the expansion of Advanced Practice Providers in specialty care environments. The need for urology clinical care will continue to grow including clinical care, access to care, care of genitourinary malignancy and education of other providers. Urologic abnormalities and diseases present with diverse clinical symptoms and signs, requiring accurate diagnosis and management that align with current standards of care. This necessitates ongoing education on the presentations of urologic conditions, the appropriate use of safe and cost-effective imaging modalities, and the latest pharmacologic and operative management options. Advancements in medical science and urology practice demand continuous learning through basic and clinical research. Specific educational needs include evidence-based guidance on management of hypogonadism and erectile dysfunction; antibiotic stewardship; Plastibell circumcisions in pediatric urology patients; and office-based cystoscopy training. These needs reflect professional practice gaps resulting from a requirement for additional knowledge, greater competence, and improved performance, and are documented through changes in the standard of care presented in national clinical guidelines (e.g., AUA), advances reported in the peer-reviewed medical and surgical literature, and data from peer-reviewed journals and consensus reports.
  • Urologist
  • Resident
  • APP
  • Non-Urologist (MD or DO)
  • Research Student
  • Nurse
  • Medical Student
After attending this CME activity, participants will be able to:

  1. Interpret recent and ongoing clinical trials across prostate, bladder, kidney, and testicular cancer and apply their findings to individualized treatment selection among surgical, systemic, and organ-sparing options.
  2. Counsel patients on the oncologic, functional, and quality-of-life trade-offs of competing oncologic strategies, incorporating comparative value and cost into shared decision-making.
  3. Describe the role of collaborative and cross-border trial consortia in generating practice-changing oncology evidence and identify opportunities for interinstitutional participation.
  4. Apply current and emerging trial data to risk-stratified, evidence-based management of benign lower-urinary-tract disease, including pediatric urinary tract infection, benign prostatic hyperplasia, and stress urinary incontinence.
  5. Evaluate minimally invasive and device-based options for benign lower-urinary-tract conditions and counsel patients on appropriate selection.
  6. Describe collaborative and practice-based research models and how trials can be conducted in non-academic settings.
  7. Describe the development and evidence base for recent surgical device advancements, instrumentation, and operative and office-based techniques in stone disease and device-based incontinence therapy.
  8. Employ new surgical tools and techniques appropriately, accounting for indications, outcomes, limitations, and differences between pediatric and adult patients.
  9. Implement recently updated clinical guidelines and contemporary, evidence-based management across clinical and sexual-medicine topics in men’s and women’s urologic health.
  10. Identify the changes in the updated clinical guidelines on management of kidney and ureteral stones and incorporate them into clinical practice.
  11. Identify, counsel, and individualize treatment for conditions within the scope of urologic care that are frequently under-recognized or under-treated, and refer appropriately when indicated.
  12. Integrate guideline updates and recent clinical-trial evidence into patient-centered, value-conscious shared decision-making across the spectrum of urologic care.
  13. Engage with collaborative and practice-based research networks to advance evidence generation in both academic and community settings.
  14. Apply antibiotic stewardship principles to optimize treatment of complicated urinary tract infections, in the presurgical and postsurgical setting.
  15. Discuss the impact of testosterone replacement therapy in men and utilize erectile dysfunction treatment algorithms.
  16. Discuss the Plastibell technique for office-based circumcision in pediatric patients
  17. Employ strategies for office-based cystoscopies in the management of benign prostatic hypertrophy (BPH), bladder cancer surveillance, botulinum toxin instillation and ureteral stent removal.
Coming Soon
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Urological Association (AUA) and the New York Section of the AUA. The AUA is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 17.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditsTM.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act 12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.